Glucotrace

Glucotrace is an injectable solution of fludeoxyglucose (18F), a radiopharmaceutical used in positron emission tomography (PET) imaging. The product is supplied as a sterile, single‑use vial for intravenous administration and is marketed in the European Union. As a glucose analog labeled with fluorine‑18, Glucotrace enables visualization of metabolic activity in various tissues and is prepared under radiopharmacy standards for clinical use.

Glucotrace is indicated for PET imaging in several clinical areas where assessment of cellular metabolism is required.

- Oncologic PET imaging to detect, stage, and monitor malignant tumors. - Cardiac PET imaging to evaluate myocardial viability and perfusion. - Neurologic PET imaging for assessment of epilepsy, dementia, and movement disorders. - Pediatric oncology imaging when appropriate radiation safety measures are applied. - Research applications investigating metabolic pathways in clinical trials. - Therapeutic response assessment in lymphoma to differentiate residual disease from treatment‑related changes.

Adverse reactions to Glucotrace are generally related to the radiopharmaceutical nature of the product and the intravenous route of administration.

Common: - Transient flushing or warmth sensation at the injection site. - Mild nausea or vomiting. - Short‑lasting headache. - Temporary metallic taste in the mouth. - Mild fatigue or dizziness. - Mild injection site pain or erythema. - Transient increase in blood glucose level.

Serious: - Allergic reactions such as urticaria, angioedema, or anaphylaxis. - Significant radiation‑induced skin erythema at the injection site. - Severe hypotension or cardiovascular collapse. - Acute renal impairment in patients with pre‑existing kidney disease. - Radiation‑induced thyroid dysfunction in susceptible individuals. - Neurological symptoms such as seizures in patients with pre‑existing CNS disease.

Glucotrace should be used only under the supervision of qualified nuclear medicine personnel, and several precautions are recommended to ensure patient safety.

- Verify patient identity and confirm indication before administration. - Assess renal function; avoid use in severe renal impairment without dose adjustment. - Ensure pregnancy status is evaluated, as fetal exposure to radiation is unknown. - Maintain appropriate radiation protection measures for staff and other patients. - Observe the patient for at least 15 minutes after injection for immediate reactions. - Document administered activity and time accurately for imaging protocol. - Use only with compatible PET/CT equipment calibrated for fluorine‑18.

Because Glucotrace is a radiopharmaceutical, drug‑drug interactions are limited, but certain agents may affect its distribution or the safety of the procedure.

Avoid: - Concurrent administration of other radiopharmaceuticals that emit positrons, which can interfere with image interpretation. - High‑dose iodinated contrast agents given immediately before PET, as they may alter biodistribution.

Use with caution: - Medications that affect glucose metabolism (e.g., insulin, oral hypoglycemics) may modify tracer uptake. - Beta‑blockers or calcium channel blockers that influence myocardial perfusion in cardiac PET studies. - Corticosteroids or chemotherapy agents that cause rapid cellular turnover, potentially affecting oncologic imaging results. - Thyroid hormone replacement therapy may increase background uptake in the neck region, requiring image interpretation adjustment.